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Joint-specific DNA methylation and transcriptome
signatures in rheumatoid arthritis identify distinct
pathogenic processes
Rizi Ai1, Deepa Hammaker2, David L. Boyle2, Rachel Morgan2, Alice M. Walsh3, Shicai Fan1,4,
Gary S. Firestein2 & Wei Wang1
Stratifying patients on the basis of molecular signatures could facilitate development of
therapeutics that target pathways specific to a particular disease or tissue location. Previous
studies suggest that pathogenesis of rheumatoid arthritis (RA) is similar in all affected joints.
Here we show that distinct DNA methylation and transcriptome signatures not only
discriminate RA fibroblast-like synoviocytes (FLS) from osteoarthritis FLS, but also
distinguish RA FLS isolated from knees and hips. Using genome-wide methods, we show
differences between RA knee and hip FLS in the methylation of genes encoding biological
pathways, such as IL-6 signalling via JAK-STATpathway. Furthermore, differentially expressed
genes are identified between knee and hip FLS using RNA-sequencing. Double-evidenced
genes that are both differentially methylated and expressed include multiple HOX genes.
Joint-specific DNA signatures suggest that RA disease mechanisms might vary from joint to
joint, thus potentially explaining some of the diversity of drug responses in RA patients.
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R
heumatoid arthritis (RA) therapy remains an unmet
medical need, despite improvement1, in part due to the
diversity of pathogenic pathways in RA2. In addition,
the methods used to assess therapeutic response in clinical trials
focus on total disease burden rather than synovitis in individual
joints3–6. The distribution of RA is generally symmetrical and
often evolves from the small joints of the hands and wrists to
more diffuse involvement. However, there is no information as to
why some joints are commonly inflamed (metacarpal phalangeal
joints), some are uncommon (distal interphalangeal joints) and
some are mainly affected in severe late disease (hips). We
hypothesized that epigenetic patterns in the unique cells that line
joints, namely fibroblast-like synoviocytes (FLS), contribute to
differences in synovial inflammation and clinical response.
Growing evidence suggests that epigenetics has an important
role in the pathogenesis of RA, which is an immune-mediated
disease affecting diarthrodial joints7,8. We previously identified a
DNA methylation signature that distinguishes RA FLS from
osteoarthritis (OA) FLS9. These cells display a unique aggressive
phenotype in RA and contribute to synovitis and matrix
destruction through the production of small-molecule
mediators, cytokines and matrix metalloproteinases9–11. By
integrating our DNA methylation data with gene expression
and genome-wide association study data, several potential drug
targets were identified12. In addition, we showed differences of
epigenomic signatures in early RA and long-standing RA
suggesting plasticity in DNA methylation over time13.
Characteristic changes of synovitis, including synovial lining
hyperplasia and sublining infiltration with mononuclear cells, are
present in many joint types during RA. However, previous studies
did not reveal significant differences in histology or cytokine
expression between various RA joints14. However, those studies
focused primarily on candidate gene approaches and used
relatively insensitive techniques, such as immunohistochemistry.
Alternative methods to assess spatially defined pathogenic
mechanisms include quantification of epigenomic marks and
transcriptomes using unbiased techniques. For example, DNA
methylation has been profiled in various human tissues, and
location-specific epigenomic patterns control tissue development
and differentiation15–21.
As joint-specific pathogenic differences could influence
response to therapy, here we evaluate DNA methylation and
gene expression signatures in hips and knees. We first expand our
RA and OA sample sets and confirm the RA epigenomic
signature in FLS. We then compare DNA methylation and the
transcriptome from FLS isolated from these two sites and identify
joint-specific signatures and pathways. These data suggest that
distinct mechanisms of disease in different joints could contribute
to the pathogenesis of RA and variable responses to therapy.
Results
Confirmation and expansion of DNA methylation signature.
We collected an independent set of 19 RA and 5 OA FLS from
total joint replacement surgeries to complement our previous data
set of 11 RA and 11 OA samples. Genome-wide analysis of DNA
methylation by Infinium HumanMethylation450 BeadChip was
used to examine methylation levels of 485,512 loci on the cultured
FLS. We first confirmed the DNA methylation signature of
RA defined in our previous work. In all, 2,956 differentially
methylated loci (DMLs) were identified between 19 RA and 5 OA,
and 72.5% overlapped with DMLs identified in the original data
set9. After mapping DMLs to gene promoter region, 71.5%
of 450 differentially methylated genes (DMGs) overlapped
(Hypergeometric test; P value¼ 4.26e-284; Supplementary
Data 1). We then identified significantly enriched pathways
related to the DMGs. In all, 13 out of 31 enriched pathways
overlapped with pathways identified previously (Hypergeometric
test; P valueo0.05; Table 1 and Supplementary Table 1).
Interestingly, multiple enriched pathways involved with
inflammation, immunity and matrix destruction, strengthening
the conclusion that the DMGs are related to mechanisms of
disease.
Next, we combined all of the samples (30 RA/16 OA)
and identified 13,577 DMLs in 1,714 DMGs in the full data set.
Sixty-seven significantly enriched pathways were identified, and
44 overlapped with the previous data, especially in pathways
involving inflammation and immune responses (Supplementary
Table 2). Using hierarchical clustering and principal component
analysis (PCA), the 30 RA and 16 OA mainly segregated into two
groups (Fig. 1a). The three possible outliers (RA_11 that clustered
with OA samples and OA_14 and OA_15 that cluster with RA
samples) shown in hierarchical clustering are positioned at edge
of the RA and OA intersection in PCA plot and indicate that they
are not outside the range for the specific disease (Fig. 1b).
Joint-specific DNA methylation signatures in RA hip/knee FLS.
The increased number of samples in our confirmatory data
set allowed us to perform separate clustering and PCA analyses
focused different individual joint locations. Hips and knees are
the most common joints requiring arthroplasty in RA and OA,
and we therefore restricted further analysis to these FLS.
Table 1 | Overlapped enriched methylation pathways between confirmatory and previous data sets.
IPA pathways Confirmtory set: 19 RA-5 OA Previous set: 11 RA-11 OA
-log (P-value) Ratio -log (P-value) Ratio
Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis 3.07 0.06 3.28 0.13
Atherosclerosis signalling 2.68 0.07 2.98 0.15
Hepatic fibrosis/hepatic stellate cell activation 2.35 0.05 4.31 0.15
Type II diabetes mellitus signalling 2.21 0.06 2.04 0.13
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis 2.04 0.04 2.22 0.11
Leukocyte extravasation signalling 1.50 0.04 2.28 0.12
ERK5 signalling 1.50 0.06 1.62 0.14
Angiopoietin signalling 1.45 0.06 1.54 0.14
DHA signalling 1.42 0.08 1.36 0.15
T helper cell differentiation 1.41 0.06 2.33 0.16
Human embryonic stem cell pluripotency 1.40 0.05 2.93 0.15
Relaxin signalling 1.39 0.05 1.50 0.11
Dendritic cell maturation 1.36 0.04 3.41 0.14
DHA, docosahexaenoic acid; IPA, Ingenuity pathway analysis; OA, osteoarthritis; Ratio, number of DMGs divided by the total number of genes in the pathway; RA, rheumatoid arthritis.
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Figure 1b shows aggregation of patient samples on the basis of
joints of origin and suggest that the methylation pattern of these
FLS could be distinguished (see also Supplementary Table 3 for
details). To define the location-specific DNA methylation sig-
natures in RA, we performed a Welch’s t-test on the methylomes
of 12 RA knee FLS and 10 RA hip FLS. A total of 3,739 DMLs
(2,232 hypermethylated and 1,507 hypomethylated in RA knee
FLS compared with hip) were identified (Supplementary Data 1).
After mapping the 3,739 DMLs to gene promoter regions,
500 DMGs were identified with 285 hypermethylated, 210
hypomethylated and 5 with both hypermethylated and
hypomethylated CpGs in RA knee FLS (Supplementary Data 1).
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Figure 1 | Unbiased clustering of a combinatory set of 30 RA and 16 OA. (a) Hierarchical clustering separated RA and OA into two groups
(with three possible outliers: RA_11, OA_14 and OA_15). The FLS origins from knee and hip were labelled with purple circle and cyan square, respectively.
The other unlabelled samples include FLS from other joints or where the source was unknown. (see Supplementary Table 3 for details). (b) PCA also
divided RA and OA with the three possible outliers (arrows) at the edge of separation, indicating that these FLS lines were within the margins for their
respective disease.
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Using 3,739 DMLs between RA knee and hip FLS, PCA separates
RA knee from hip FLS with one RA knee FLS located at the edge
of RA hip (Fig. 2a).
Comparison of RA knee/hip differences to RA/OA differences.
We then consider how the within-disease RA joint-specific
differences compared with the overall differences between RA
and OA. The number of RA knee/hip DMLs was 72.4% lower
than the number RA/OA DMLs, suggesting that distinction
between RA knee/hip is quantitatively less than the difference
between RA and OA. Further analysis show that 391 (10.5%) of
3,739 RA knee/hip DMLs overlap with 13,577 RA/OA DMLs
defined in our combined data set (30 RA and 16 OA).
DNA methylation signatures in OA knee and OA hip joints.
DNA methylation loci that differentiate OA knee and OA hip
joints were then examined (Fig. 2b). A total of 6,416 DMLs
(3,820 hypermethylated and 2,596 hypomethylated) in the
promoter region of 814 DMGs (467 hypermethylated,
336 hypomethylated and 11 with both hypermethylated and
hypomethylated DMLs) were identified between OA knee and hip
FLS (Supplementary Data 1). 2,178 DMLs of the total 3,739 RA
knee/hip DMLs overlap with the OA knee/hip DMLs. These
overlapped DMLs could represent joint-specific methylation
patterns that are independent of disease and instead reflect
location-specific epigenetic marks, that is, a pattern that defines a
hip FLS from a knee FLS.
Disease-specific differences in knees and hips. Because the DNA
methylation of 30 RA and 16 OA FLS were compared previously
as a group, we also performed RA/OA comparisons within knees
(12 RA to 10 OA) and within hips (10 RA to 5 OA), respectively
(Supplementary Fig 1a,b). In all, 9,589 DMLs and 1,275 DMGs
were identified between RA and OA knee FLS and 2,172 DMLs
and 373 DMGs between RA and OA hip joint FLS. Of interest,
1,315 RA/OA DMLs overlapped between hips and knees. The
majority of these DMLs (87.9% and 80.6% of between-disease
DMLs in knees and hips, respectively) overlapped with the pre-
viously identified 13,577 RA/OA DMLs in combined data set (30
RA and 16 OA). The data indicate that the disease differences are
still consistent in these two joints. The DMLs and DMGs are
listed in the Supplementary Data 1.
Joint-specific biological pathway identification. To examine
disease-specific enriched pathways in different RA joints based on
DNA methylation, we compared RA knee with hip FLS and then
removed pathways potentially due to non-RA-associated
influences because they were also found in OA FLS. Twelve RA
knee and 10 OA knee FLS were combined and compared with 10
RA hip and 5 OA hip FLS combined. Optimally, normal FLS
would be used for this analysis, but these samples are difficult to
obtain and usually lack annotation to definitively exclude joint
disease. As a surrogate, we used the RA–OA joint combination
to help exclude some non-specific pathways. Eleven unique dif-
ferentially methylated biological pathways (Hypergeometric test;
P valueo0.05) were found between RA knee and RA hip FLS
(Table 2). Of particular interest are IL-6 signalling via JAK-STAT,
which suggested that IL-6-related mechanisms might distinguish
hips and knees. To test this hypothesis, IL-6 expression was
measured in whole hip and knee synovia; IL-6 expression was
10.8-fold higher in RA hips than knees (two-tailed unpaired t-test
with Welch’s correction; P-value¼ 0.042; n¼ 13 RA hip, 22 RA
knee, 13 OA hip, 15 OA knee; Fig. 3). Of interest, IL-6 expression
was also higher in OA hip compared with OA knee FLS
(two-tailed unpaired t-test with Welch’s corrections; fold
difference¼ 3.72; P-value¼ 0.027).
Biological validation of joint-specific FLS function. To deter-
mine whether the differences between hip and knee FLS extend to
FLS function, we performed RNA sequencing (RNA-seq)
experiments on 5 RA hip and 4 RA knee FLS lines. We identified
107 differentially expressed genes (DEGs) comparing RA hip and
knee FLS (Supplementary Data 1). PCA shows that RA knee and
RA hip FLS segregate from each other (Fig. 4). The enriched
biological pathways related to the DEGs are shown in Table 3.
Of interest, the ‘IL-6 signalling’ pathway previously shown for
DMGs was also observed for the RA knee and hip transcriptomes.
Comparing 495 hyper- or hypo-DMGs, ten genes overlap
(SORBS2, HOXD3, LDLRAD4, EMB, HOXD10, HOXD9,
HOXD-AS1, WNT5A, HOXB2, HAND2). The overlap with
genes associated with development, such as HOX and WNT, is
especially striking. As a control, we also test pathways enrichment
by randomly picking 10 groups of 107 human genes and
performing pathway analysis. As expected, some of these gene
sets reach statistical significance. However, in contrast to our
RNA-seq data, the number of ‘enriched’ pathways is much
smaller for each gene set (usually five to ten) and the pathways
are quite random and not related to immune function (data
not shown).
Potential therapeutic implications. To explore how differences
in methylation and gene expression could affect joint-specific
responses to drugs, we compiled a partial list of relevant
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Figure 2 | PCA of RA and OA joints by knee or hip methylation
signatures. (a) Separation of RA knee and RA hip FLS using 3,739 DMLs.
(b) Separation of OA knee and OA hip using the 6,416 DMLs. See text for
description of how these DMLs were identified.
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anti-rheumatic drugs approved for use, in clinical trials or
discontinued. This list of RA drugs was then assigned to the drug
targets in joint-specific enriched RA knee or hip biological
pathways (Table 2). Figure 5 shows one example of this analysis
focused on the pathway ‘role of JAK family kinases in IL-6-type
cytokine signalling’. Six RA drug targets were identified in the
pathway, including IL-6, JAK1, JAK2, Tyk2, p38 MAPK
and ERK1/2. Among the assigned RA drugs, tocilizumab and
tofacitinib that target IL-6 and JAKs, respectively, are currently
approved for use in RA. It is worth noting that several promising
drugs with abundant pre-clinical data had only modest or no
efficacy in RA, such as MEK and p38 inhibitors. Based on
our data, we speculate that efficacy could have been under (or
over) estimated if joint-specific pathways were not taken into
account.
Discussion
Our studies demonstrate joint location-specific epigenetic marks
that could contribute to local pathogenic and developmental
mechanisms. We focused on FLS for a variety of reasons, most
notably because they display a unique aggressive phenotype in RA
and contribute to cytokine production and joint damage. They
also have not been targeted by new therapeutics and are a
treatment opportunity that would not affect adaptive immunity22.
Finally, FLS are a homogeneous population compared with the
Table 2 | Unique differentially methylated pathways between RA knee and hip FLS.
Unique RA-knee versus RA-hip
pathways
-log
(P-value)
Ratio Drug targets Drugs
IL-17A signalling in airway cells 1.98 0.08 IL-6, JAK1, JAK2,
JAK3,
p38 MAPK, IL-17A,
NFkB, PI3K,
MEK1/2
Tocilizumab*, sirukumabw, MEDI5117w, ALX-0061w, sarilumabw,
olokizumabw, tofacitinib*, baracitinibw, peficitnibw, ruxolitinibw,
INCB39110w, CYT387w, filgotinibw, PF-956980w, decernotinibw, R-348z,
PH-797804z, BMS-582949z, ARRY-371797z, dilmapimodz, VX-702z,
pamapimodz, VX-745z, talmapimodz, AMG-548z, doramapimodz,
secukinumabw, ixekizumabw, brodalumabw, iguratimodw (approved in
China and Japan), CAL-263w, duvelisibz, idelalisibz, ARRY-162z,
PD98059z, AZD8055z
IL-22 signalling 1.87 0.13 JAK1, Tyk2, p38
MAPK,
ERK1/2
Tofacitinib*, baracitinibw, peficitnibw, ruxolitinibw, INCB39110w, CYT387w,
filgotinibw, fezakinumabz, PH-797804z, BMS-582949z, ARRY-371797z,
dilmapimodz, VX-702z, pamapimodz, VX-745z, talmapimodz, AMG-548z,
doramapimodz, ARRY-162z, PD98059z, AZD8055z
Role of JAK family kinases in
IL-6-type cytokine signalling
1.82 0.12 IL-6, JAK1, JAK2,
Tyk2,
p38 MAPK,
ERK1/2
Tocilizumab*, sirukumabw, MEDI5117w, ALX-0061w, sarilumabw,
olokizumabw, tofacitinib*, baracitinibw, peficitnibw, ruxolitinibw,
INCB39110w, CYT387w, filgotinibw, fezakinumabz, PH-797804z,
BMS-582949z, ARRY-371797z, dilmapimodz, VX-702z, pamapimodz,
VX-745z, talmapimodz, AMG-548z, doramapimodz, ARRY-162z,
PD98059z, AZD8055z
p53 signalling 1.82 0.06 p38 MAPK, PI3K PH-797804z, BMS-582949z, ARRY-371797z, dilmapimodz, VX-702z,
pamapimodz, VX-745z, talmapimodz, AMG-548z, doramapimodz,
CAL-263w, duvelisibz, idelalisibz
IL-17 signalling 1.77 0.07 IL-6, COX2, JAK1,
JAK2,
p38 MAPK, PI3K,
iNOS,
MEK1/2, CRP,
CXCL10
Tocilizumab*, sirukumabw, MEDI5117w, ALX-0061w, sarilumabw,
olokizumabw, NSAIDs*, tofacitinib*, baracitinibw, peficitnibw, ruxolitinibw,
INCB39110w, CYT387w, filgotinibw, PH-797804z, BMS-582949z,
ARRY-371797z, dilmapimodz, VX-702z, pamapimodz, VX-745z,
talmapimodz, AMG-548z, doramapimodz, CAL-263, duvelisibz, idelalisibz,
GW274150z, ARRY-162z, PD98059z, AZD8055z, ISIS-CRPz, eldelumabz
2-Amino-3-carboxymuconate
semialdehyde degradation
to glutaryl-CoA
1.68 1.00 NA NA
Retinoate biosynthesis I 1.55 0.07 NA NA
Inhibition of angiogenesis
by TSP1
1.53 0.09 p38 MAPK PH-797804z, BMS-582949z, ARRY-371797z, dilmapimodz, VX-702z,
pamapimodz, VX-745z, talmapimodz, AMG-548z, doramapimodz
TGF-b signalling 1.46 0.06 p38 MAPK,
MEK1/2
PH-797804z, BMS-582949z, ARRY-371797z, dilmapimodz, VX-702z,
pamapimodz, VX-745z, talmapimodz, AMG-548z, doramapimodz,
ARRY-162z, PD98059z, AZD8055z
Acute phase response signalling 1.3 0.04 TNF, IL-1, GCR,
IL-6,
p38 MAPK, JAK2,
CRP, C5a,
mTOR, NFkB, PI3K,
MEK1/2
Etanercept*, infliximab*, adalimumab*, certolizumab pegol*, golimumab*,
SSR150106, anakinra*, canakinumabw, GSK1827771z, corticosteroids*,
tocilizumab*, sirukumabw, MEDI5117w, ALX-0061w, sarilumabw,
olokizumabw, PH-797804z, BMS-582949z, ARRY-371797z, dilmapimodz,
VX-702z, pamapimodz, VX-745z, talmapimodz, AMG-548z,
doramapimodz, baracitinibw, ruxolitinibw, CYT387w, ISIS-CRPz, NN 8209z,
NN 8210z, eculizumabz, MP-435z, temsirolimusw, iguratimodw (approved
in China and Japan), CAL-263w, duvelisibz, idelalisibz, ARRY-162z,
PD98059z, AZD8055z
Death receptor signalling 1.3 0.03 TNF, NFkB Etanercept*, infliximab*, adalimumab*, certolizumab pegol*, golimumab*,
SSR150106w, iguratimodw (approved in China and Japan)
FLS, fibroblast-like synoviocyte; NA, not applicable; RA, rheumatoid arthritis; NA, not applicable; Ratio, number of DMGs divided by the total number of genes in the pathway.
*Currently approved in the USA for RA.
wIn clinical development at the time of publication.
zDiscontinued.
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mixture of cells that populate the inflamed synovium and create
complexity when trying to deconvolute data.
Using FLS and the expanded data set, we first confirmed the
DNA methylation signature of RA defined in our previous study.
We then showed that RA FLS have distinct DNA methylation and
gene expression patterns based on the joint of origin. These data
suggest that joints might differentially respond to highly targeted
therapeutic agents and that this possibility should be considered
in clinical trial design.
Our analysis has potential limitations, in part, because of the
nature of arthroplasty surgery today. Hip and knee surgeries are
the most common in RA and OA, which limits our ability to
sample enough synovia from other joints. We also could not
compare within-patient samples (that is, hip and knee from
the same patient) because patients rarely have simultaneous
arthroplasties. The use of cultured FLS introduces potential for
the influence of culture conditions; current technology precluded
the use of ‘primary’ FLS. Nevertheless, the FLS methylation
profile is stable despite prolonged culture and the aggressive FLS
phenotype is maintained for months after isolating from synovial
tissue9,23. Furthermore, hip and knee FLS were purified and
grown the same way but still had very different methylomes
and transcriptomes. Finally, our population is enriched for
longstanding disease, which would be an advantage because it
decreases the potential for epigenetic differences that might be
based on duration of disease13. Despite these limitations, RA- and
joint-specific genes and pathways were identified suggesting
distinct pathogenic mechanisms can be identified even when
potential disease-independent differences were taken into account.
The notion that all joints exhibit similar pathology in RA has
been evaluated. For example, no significant differences in
histology and cytokine expression in various joints were observed
using immunohistochemistry14. The differences between our
results and previous studies are likely due to the sensitivity of
techniques and the use of unbiased rather than candidate gene
approaches. One interesting corollary relates to the observation
that FLS can potentially migrate from joint to joint24. Therefore,
location-specific signatures suggest that local conditions could
shape the epigenome after cells arrive.
We also compared the magnitude of RA hip/knee differences
with RA/OA differences using computational methods. As
expected, within-disease changes (for example, RA hip to RA
knee) were less than the differences between RA and OA.
Pathways and genes that are most likely related to hip and knee
development because they were shared across diseases were
estimated and subtracted from the RA hip and knee data to
estimate RA-specific changes. The RA hip- or knee-specific
pathways are related to inflammation and immune responses and
support the notion that RA joints could have distinct pathogenic
mechanisms.
Among the differences between hips and knees, we were struck
by the preponderance of developmental genes that emerged in
both transcriptomics and methylomics studies. The highly
conserved HOX genes encode transcription factors of embryonic
development that regulate limb morphogenesis and skeletal
formation. During vertebrate embryo development, the HOX
genes specify regional differences along the anterior–posterior
axis25. The location-specific expression of HOX genes might
contribute to defining joint-specific biology and function, and the
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Figure 4 | PCA of RA knee and RA hip FLS by differential gene
expression analysis using RNA-seq. Distinct gene expression patterns
were demonstrated that separated knee and hip transcriptomes. The PCA
plot was generated using 107 DEGs between RA knee and hip FLS,
with gene expression fold-change 42 and Benjamini–Hochberg adjusted
P-valueso0.05.
Table 3 | Differentially expressed pathways between RA
knee and hip FLS.
IPA pathways -log
(P-value)
Ratio
Coagulation system 3.44 0.10
Acute phase response signalling 2.19 0.03
Glutamate-dependent acid resistance 2.03 0.50
Hepatic fibrosis/hepatic stellate cell activation 2.01 0.02
IL-6 signalling 1.78 0.03
Protein citrullination 1.73 0.25
Glutamate degradation III (via 4-aminobutyrate) 1.64 0.20
Wnt/Caþ pathway 1.58 0.04
Gaq signalling 1.53 0.02
Gap junction signalling 1.52 0.02
Tryptophan degradation to 2-amino-3-
carboxymuconate semialdehyde
1.49 0.14
Salvage pathways of pyrimidine deoxyribonucleotides 1.43 0.13
Growth hormone signalling 1.41 0.03
Extrinsic prothrombin activation pathway 1.23 0.08
NAD biosynthesis II (from tryptophan) 1.23 0.08
Role of tissue factor in cancer 1.07 0.02
Type I diabetes mellitus signalling 1.06 0.02
Tryptophan degradation III (eukaryotic) 1.05 0.05
Sperm motility 1.02 0.02
Cellular effects of sildenafil 1.01 0.02
FLS, fibroblast-like synoviocyte; IPA, Ingenuity Pathway Analysis (see Methods); Ratio, number
of DEGs divided by the total number of genes in the pathway; RA, rheumatoid arthritis.
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impact on pathogenesis of disease is not fully understood.
Differential expression of HOX genes in RA has been previously
identified and supports the notion that the genes and pathways
are not random26–28.
The clinical relevance of joint-specific pathways could be
important when considering how drugs are tested in RA clinical
trials. Current metrics do not distinguish which joints respond;
instead, only the total number of swollen and tender joints is
counted. Thus, investigators could potentially overlook site-
specific responses or patterns. Hips are rarely evaluated in most
clinical trial tools, such as the DAS28 (refs 29,30), so a differential
response in the hip would be missed entirely. Thus, clinical
trialists had no method to determine whether individual joints
differentially respond to targeted agents; to date, there was no
particular reason to do so to consider this issue. Because our
study found location-specific methylation and transcriptome
signatures, it raises the possibility that asynchronous responses
might occur with RA therapies. Although speculative, this could
be an important consideration that in the context of clinical trials.
In conclusion, we have shown joint-specific differences in
epigenetic imprinting and gene expression. Some of these
differences could be due to the role of FLS in joint development.
However, RA-specific differential gene expression and methyla-
tion pathways are also evident. The methylome and transcrip-
tome differences between knees and hips in RA could potentially
contribute to differential responses to highly targeted agents.
Methods
Synovial tissue and cell culture conditions. This study was approved by the
Institutional Review Board of University of California, San Diego School of
Medicine, and informed consent was obtained from all participants. Synovial tissue
was obtained from patients with RA and OA at the time of total joint replacement
or synovectomy, as previously described. In addition to the confirmatory samples,
previously 11 RA and 11 OA (all female) reported synovial tissues were obtained
with the same methods under the same Institutional Review Board approval.9,10
The diagnosis of RA conformed to American College of Rheumatology 2010
criteria31. The synovium was minced and incubated with 0.5mgml 1 collagenase
type VIII (Sigma-Aldrich) in serum-free RPMI-1640 (Life Technologies) for 1 h at
37 C, filtered, extensively washed and cultured in DMEM (Life Technologies)
supplemented with 10% heat-inactivated fetal bovine serum (Gemini Bio Products)
and supplements (penicillin, streptomycin, gentamicin and glutamine) in a
humidified 5% CO2 atmosphere. Cells were allowed to adhere overnight,
non-adherent cells were removed. Adherent FLSs were split at 1:3 when 70–80%
confluent and used from passages 4 through 7 (ref. 32). Optimally, normal FLS
would also be used for this analysis, but these samples are difficult to obtain and
usually lack annotation to definitively exclude joint disease.
FLS and patient phenotypes. Genomic DNA from RA (n¼ 19; all female; average
age 56) and OA (n¼ 5; all female; average age 66) FLSs were isolated from patients
requiring total joint replacements. Among the total 30 RA samples, 12 FLS were
obtained from patient knees and 10 were from hips. Of 16 OA samples, 10 FLS
were from knees and 5 were from hips. The origins of other joint samples are listed
in Supplementary Table 3. Because some samples were de-identified, the joint of
origin was not known. These samples were included in the overall assessment of
RA compared with OA but not in the hip versus knee comparison.
BeadChip analysis. DNA methylation level was measured using the Illumina
Infinium HumanMethylation450 chip and processed with minfi package in R.
The combined data set including 30 RAs and 16 OAs were normalized via the
wateRmelon package in R (dasen function). CpGs with more than three detection
P-values40.01 were filtered out for OA and RA at each locus. The methylation
level at individual locus was reported as b values, which varies from 0
(unmethylated) to 1 (fully methylated).
DML and DMG identification. A Welch’s t-test was performed to identify the
significant DMLs. The P-values were subjected to a multiple testing correction
and converted to q values using fdrtool package in R. To consider a DML,
two conditions were used: (i) the differences of average b values were greater than
0.1 and (ii) q values were less than 0.05. DMLs located in the gene promoter
regions were assigned to the corresponding genes, which were defined as DMGs.
A promoter region of a gene is defined as  2,500 to 500 bps from the transcription
start site. RefSeq genes, obtained from Genome Browser in University of California,
Santa Cruz, were used to define the gene regions.
PH-797804, BMS-582949,
ARRY-37179, dilmapimod,
VX-702, pamapimod,
VX-745, talmapimod,
AMG-548, doramapimod
ARRY-162, PD98059, AZD8055
Tocilizumab*, sirukumab, MEDI5117,
ALX-0061, sarilumab, olokizumab
Tofacitinib*, baracitinib,
peficitinib, ruxolitinib,
INCB39110, CYT387,
filgotinib
 
Baracitinib,
ruxolitinib, CYT387
Fezakinumab
Extracellular space Extracellular space
Cytoplasm
Nucleus Nucleus
Cytoplasm
Figure 5 | Representative joint-specific enriched biological pathway. The ingenuity pathway analysis ‘role of JAK family kinases in IL-6-type cytokine
signalling’ pathway is shown along with RA drug targets and anti-rheumatic drugs approved for use, in clinical trials or discontinued. Six RA drug targets were
identified that have potential for differential responses between hips and knees, including IL-6, JAK1, JAK2, Tyk2, p38 MAPK and ERK1/2. Among the assigned RA
drugs, tocilizumab and tofacitinib (labelled with *) that target IL-6 and JAKs, respectively, are currently approved for use in RA in the United States. The network
was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPAs, QIAGEN Redwood City, www.qiagen.com/ingenuity)
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Hierarchical clustering and PCA. Based on defined DML sets, hierarchical
clustering was performed using heatmap.2 function in R. Pearson correlation
was used to calculate the distance matrix and UPGMA was adopted as the
agglomeration method in hierarchical clustering. PCA was also performed to assess
the relationships between different FLS types by FactoMineR (PCA function) in R.
Unique RA knee and hip pathway enrichment analysis. To identify
distinguished pathways, DMGs were mapped to Ingenuity pathway analysis
(Qiagen; www.qiagen.com/ingenuity) and evaluated for enrichment. To identify
the unique RA knee and hip pathways, (i) enriched biological pathways were
combined using all DMGs, hypermethylated DMGs and hypomethylated DMGs
between 12 RA knee and 10 RA hip; (ii) to avoid the RA-independent differences
between knees and hips, knee FLS were represented by combining 12 RA-knee FLS
and 10 OA-knee FLS, whereas hip FLS by combining 10 RA-hip FLS and 5 OA-hip
FLS. All/hypermethylated/hypomethylated DMGs were identified and enriched
biological pathways were combined; (iii) then, the unique pathways that distinguish
RA knee and RA hip FLS were computed as by excluding pathways identified in
(ii) from (i). To allow more enriched pathways included at each step, P-value cutoff
of 0.1 was used. The final combined list only displayed unique pathways with
P-valueso0.05.
Assigning RA drugs to uniquely enriched pathways. A list of current
therapeutics to treat RA was obtained through the American College of
Rheumatology website and the 2012 clinical practice guide33. Drugs in clinical trials
were identified through the clinicaltrials.gov website and a literature search for RA
clinical trials. Drugs were included if they are in use for, are currently under testing
for or have been tried for RA. Ingenuity pathway analysis was used to analyse the
pathways and cross-reference with the list of drug targets.
RNA-seq data generation and processing. Total RNA was extracted and the
quality of all samples was evaluated using an Agilent Bioanalyzer (Agilent). The
samples had an average RNA integrity number of 9.4 with a minimum of 7.5.
Sequencing libraries were prepared using TruSeq Stranded Total RNA RiboZero
protocol from Illumina with an input of 400 ng RNA. Libraries were pooled and
sequenced with an Illumina HiSeq 2000 with paired-end 100 bp flow cell. The
average number of reads per sample was 171.8 million reads with a minimum of
154.5 million reads. Data were demultiplexed using Illlumina’s CASAVA software.
Raw read quality was evaluated using FastQC.
Adapter and low-quality bases below a quality score of 15 were trimmed from
raw RNA-seq reads using Cutadapt. After trimming, reads with less than 30 bp
were further discarded. The remaining reads were aligned to human reference
genome hg19 using STAR (2.3.0) and assembled and quantified by HTSeq
(0.5.4p5). DEGs were identified using DESeq2 package in R. To consider a DEG,
twofold change of gene expression levels between RA knee and RA hip should be
achieved and the Benjamini–Hochberg adjusted P-value is less than 0.05. For the
following analysis, transcription levels were then converted to log2 of the
normalized counts.
Quantitative real-time PCR. Total RNA from synovial tissue was isolated using
RNASTAT-60 and reverse transcribed (Applied Biosystems). The cDNA served as
template for amplification by qPCR using TaqMan Gene Expression assays
(StepOnePlus Instruments, Applied Biosystems). Data are presented as relative
expression units, which uses the standard curve method and normalizes the Ct
values to b-actin34. Primers were purchased from Life Technologies.
Data availability. Data that support the findings of this study have been deposited
in Gene Expression Omnibus with the accession codes GSE80071 and GSE80072.
Data referenced in this study are available in Gene Expression Omnibus with
the accession code GSE46364. All other relevant data are available from the
corresponding authors.
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